Cytokinetics price target raised to $69 from $61 at UBS

UBS raised the firm’s price target on Cytokinetics (CYTK) to $69 from $61 and keeps a Neutral rating on the shares. Analysis of the nHCM program modestly improves the perceived probability of success for the ACACIA trial to about 50%, though the upcoming Q2 readout remains a binary catalyst due to disease complexity and a mixed patient population, the analyst tells investors in a research note. Early signs from the oHCM launch, such as rapid REMS certification, suggest encouraging momentum, but meaningful updates are unlikely until later in 2026, the firm says.